REGN vs SYM · P/E 14, rev $14.34B vs rev $2.25B
Regeneron Pharmaceuticals Inc (REGN) versus Symbotic Inc (SYM) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Symbotic Inc (SYM) is a specialty industrial machinery company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SYM revenue for 2025-09-27 was $2.25B. Net income was -$91.0M. Revenue was up 298.0% from 2024-09-28 to 2025-09-27. SYM currently screens at market cap $24.25B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SYM currently screens at market cap $24.25B.
Not investment advice. Open the REGN and SYM stock pages for the full models.
Not investment advice.